Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in diabetic nephropathy
IRCT20210906052395N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of empagliflozin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Change in glomerular filtration rate and Change in albuminuria. Started Sep 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20210906052395N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210906052395N1.